Breast Cancer Coverage from Every Angle

Adding a Tumor Bed Boost to Whole-Breast Irradiation for Ductal Carcinoma in Situ

By: Julia Fiederlein
Posted: Friday, January 22, 2021

According to Boon Hui Chua, MBBS, of the University of New South Wales, Sydney, and colleagues, patients with ductal carcinoma in situ who received a tumor bed boost after conventional or hypofractionated whole-breast irradiation seemed to experience significantly reduced rates of local recurrence. The multicenter phase III BIG3-07/TROG 07.01 trial results were presented during the virtual 2020 San Antonio Breast Cancer Symposium (SABCS; Abstract GS2-04).

A total of 1,608 patients were assigned to receive conventional (50 Gy in 25 daily fractions) or hypofractionated (42.5 Gy in 16 daily fractions) whole-breast irradiation with or without a tumor bed boost (16 Gy in 8 daily fractions) in one of three randomization categories. Those in randomization A underwent either conventional or hypofractionated whole-breast irradiation with or without a boost. Patients in randomizations B and C received conventional and hypofractionated whole-breast irradiation, respectively, with or without a boost.

The 5-year free-from-local-recurrence rates with and without the boost were 97% versus 93%, respectively (P < .001). Invasive local recurrences occurred in 45% of patients treated with the boost and in 44% of those without. The boost's effect did not seem to be significantly impacted by age, tumor size, nuclear grade, surgical margin, or endocrine therapy.

The 5-year free-from-local-recurrence rates did not seem to differ between the conventional and hypofractionated whole-breast irradiation groups in randomization A (both 94%; P = .84) and in all randomly assigned patients (both 95%; P = .89). Additionally, the interaction between boost and dose fractionation did not appear to be significant in randomization A or in all randomly assigned patients (both P = .89). The rates of breast pain (grade ≥ 2: 12% vs. 16%; P = .84) and skin and subcutaneous tissue fibrosis (6% vs.15%; P = .14) did not seem to significantly differ between the groups.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.